IP Library Granted Patent US 11,582,994
Granted Patent B2
US 11,582,994 · App. 16/770,224 · Granted Feb 21, 2023

Spray-dried 3-fucosyllactose

Inventor: Stefan Jennewein (Bad Honnef, DE)
Assignee: Chr. Hansen HMO GmbH
A23L33/125A23C9/206A23L3/46A23L5/273A23L29/065A23L33/135A23L33/18A23L33/40A23P10/40A61K35/741A61K47/26B01D9/005B01D9/0018B01D61/027B01D61/145B01D61/422B01D61/58C07H1/00C07H1/06C07H3/06C12N9/12C12P17/181C12P19/00A23V2002/00B01D2009/0086B01D2311/02B01D2311/2623B01D2311/2626
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,582,994
App. No.
16/770,224
Granted
Feb 21, 2023
Kind
B2
Abstract

Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-fucosyllactose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.

Claims (30)

1. A nutritional composition comprising a spray-dried powder,

wherein the spray-dried powder comprises at least 80%-wt. 3-fucosyllactose which has been produced by microbial fermentation,

wherein the spray-dried powder contains ≤15%-wt. of water and is free of genetically-engineered microorganisms and nucleic acid molecules derived from genetically-engineered microorganisms, and

wherein the nutritional composition further comprises at least one probiotic microorganism.

2. The nutritional composition of claim 1 , wherein the spray-dried powder comprises at least 85%-wt 3-fucosyllactose.

3. The nutritional composition of claim 1 , wherein the 3-fucosyllactose is present in amorphous form.

4. The nutritional composition of claim 1 , wherein the spray-dried powder comprises ≤7%-wt. of water.

5. A process for the manufacture of the spray-dried powder of the nutritional composition of claim 1 , wherein the process comprises

a) purifying the 3-fucosyllactose from a fermentation broth;

b) providing an aqueous solution containing the 3-fucosyllactose of a); and

c) subjecting the solution of b) to spray-drying to obtain the spray-dried powder.

6. The process according to claim 5 , wherein the purifying the 3-fucosyllactose from a fermentation broth a) includes one or more of

i) removing the microbial cells from the fermentation broth to obtain a cleared process stream;

ii) subjecting the cleared process stream to at least one ultrafiltration;

iii) treating the cleared process stream at least one time with a cation exchange resin and/or at least one time with an anion exchange resin;

iv) subjecting the cleared process stream to at least one nanofiltration and/or diafiltration;

v) subjecting the cleared process stream to at least one electrodialysis;

vi) treating the cleared process stream at least one time with activated charcoal; and/or

vii) subjecting the cleared process stream at least one time to a crystallization and/or precipitation.

7. The process according to claim 5 , wherein the aqueous solution comprises the 3-fucosyllactose in an amount of at least 20% (w/v), optionally at least 30% (w/v), and optionally at least 35% (w/v), and up to 45% (w/v), optionally at least 50% (w/v), and optionally at least 60% (w/v).

8. The process according to claim 5 , wherein the aqueous solution comprising the 3-fucosyllactose is spray dried at a nozzle temperature of at least 110° C., optionally at least 120° C., optionally at least 125° C., and less than 150° C., optionally less than 140° C., and optionally less than 135° C.

9. The process according to claim 5 , wherein the aqueous solution comprising the 3-fucosyllactose is spray-dried at an outlet temperature of at least 60° C., optionally at least 65° C., and less than 80° C., optionally less than 70° C.

10. The nutritional composition of claim 1 , wherein the nutritional composition is an infant formula.

11. The nutritional composition of claim 1 , further comprising at least one additional HMO, wherein said at least one additional HMO is a neutral HMO or a sialylated HMO.

12. The nutritional composition of claim 11 wherein the at least one neutral HMO is selected from the group consisting of 2′-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose and lacto-N-fucopentaose I.

13. The nutritional composition of claim 11 , wherein the at least one sialylated HMO is selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, sialyllacto-N-tetraose (LST)-a, LST-b, LST-c and disialyllacto-N-tetraose.

14. The nutritional composition of claim 2 , wherein the spray dried powder comprises at least 90%-wt 3-fucosyllactose.

15. The nutritional composition of claim 2 , wherein the spray dried powder comprises at least 98%-wt 3-fucosyllactose.

16. The nutritional composition of claim 1 , wherein the spray dried powder comprises ≤10%-wt. of water.

17. The nutritional composition of claim 1 , wherein the spray dried powder consists essentially of 3-fucosyllactose.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2020
From: JENNEWEIN, STEFAN
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 053681/0971 →
Priority Claims (5)
EP 17206124 · Dec 8, 2017 · regional
EP 17206159 · Dec 8, 2017 · regional
EP 17206223 · Dec 8, 2017 · regional
EP 17206414 · Dec 11, 2017 · regional
EP 18155669 · Feb 8, 2018 · regional
Continuity (1)
Related Publication 20210171992A1 · Jun 10, 2021